List of DeuteRx patents

Patents where

Current Assignee

Name

‌

DeuteRx

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 9732031 Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion	Patent 9732031 was granted and assigned to DeuteRx on August, 2017 by the United States Patent and Trademark Office.	‌ DeuteRx	‌ DeuteRx	United States Patent and Trademark Office	9732031	August 15, 2017
‌ US Patent 9809603 Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same	Patent 9809603 was granted and assigned to DeuteRx on November, 2017 by the United States Patent and Trademark Office.	‌ DeuteRx	‌ DeuteRx	United States Patent and Trademark Office	9809603	November 7, 2017
‌ US Patent 11535603 Deuterium-enriched piperidinonyl-oxoisoindolinyl acetamides and methods of treating medical disorders using same	Patent 11535603 was granted and assigned to DeuteRx on December, 2022 by the United States Patent and Trademark Office.	‌ DeuteRx	‌ DeuteRx	United States Patent and Trademark Office	11535603	December 27, 2022
‌ US Patent 11491156 3-(substituted-4-oxoquinazolin-3(4	Patent 11491156 was granted and assigned to DeuteRx on November, 2022 by the United States Patent and Trademark Office.	‌ DeuteRx	‌ DeuteRx	United States Patent and Trademark Office	11491156	November 8, 2022
‌ US Patent 9090585 2,6-dioxo-3-deutero-piperdin-3-yl-isoindoline compounds	Patent 9090585 was granted and assigned to DeuteRx on July, 2015 by the United States Patent and Trademark Office.		‌ DeuteRx	United States Patent and Trademark Office	9090585	July 28, 2015
‌ US Patent 8722710 Deuterium-enriched pioglitazone	Patent 8722710 was granted and assigned to DeuteRx on May, 2014 by the United States Patent and Trademark Office.		‌ DeuteRx	United States Patent and Trademark Office	8722710	May 13, 2014
‌ US Patent 10188639 Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone	Patent 10188639 was granted and assigned to DeuteRx on January, 2019 by the United States Patent and Trademark Office.	‌ DeuteRx	‌ DeuteRx	United States Patent and Trademark Office	10188639	January 29, 2019
‌ US Patent 9416117 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same	Patent 9416117 was granted and assigned to DeuteRx on August, 2016 by the United States Patent and Trademark Office.	‌ DeuteRx	‌ DeuteRx	United States Patent and Trademark Office	9416117	August 16, 2016
‌ US Patent 9540340 3-(5-substituted-4-oxoquinazolin-3(4	Patent 9540340 was granted and assigned to DeuteRx on January, 2017 by the United States Patent and Trademark Office.	‌ DeuteRx	‌ DeuteRx	United States Patent and Trademark Office	9540340	January 10, 2017
‌ US Patent 10189858 Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same	Patent 10189858 was granted and assigned to DeuteRx on January, 2019 by the United States Patent and Trademark Office.	‌ DeuteRx	‌ DeuteRx	United States Patent and Trademark Office	10189858	January 29, 2019
‌ US Patent 9290475 3-(substituted-4-oxoquinazolin-3(4	Patent 9290475 was granted and assigned to DeuteRx on March, 2016 by the United States Patent and Trademark Office.	‌ DeuteRx	‌ DeuteRx	United States Patent and Trademark Office	9290475	March 22, 2016
‌ US Patent 8669275 Deuterium-enriched donepezil	Patent 8669275 was granted and assigned to DeuteRx on March, 2014 by the United States Patent and Trademark Office.	‌ DeuteRx	‌ DeuteRx	United States Patent and Trademark Office	8669275	March 11, 2014
‌ US Patent 9833445 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same	Patent 9833445 was granted and assigned to DeuteRx on December, 2017 by the United States Patent and Trademark Office.	‌ DeuteRx	‌ DeuteRx	United States Patent and Trademark Office	9833445	December 5, 2017
‌ US Patent 8735454 Deuterium-enriched bupropion	Patent 8735454 was granted and assigned to DeuteRx on May, 2014 by the United States Patent and Trademark Office.	‌ DeuteRx	‌ DeuteRx	United States Patent and Trademark Office	8735454	May 27, 2014
‌ US Patent 8969581 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same	Patent 8969581 was granted and assigned to DeuteRx on March, 2015 by the United States Patent and Trademark Office.	‌ DeuteRx	‌ DeuteRx	United States Patent and Trademark Office	8969581	March 3, 2015
‌ US Patent 9925175 Deuterium-enriched pioglitazone	Patent 9925175 was granted and assigned to DeuteRx on March, 2018 by the United States Patent and Trademark Office.	‌ DeuteRx	‌ DeuteRx	United States Patent and Trademark Office	9925175	March 27, 2018
‌ US Patent 8524780 Deuterium-enriched bupropion	Patent 8524780 was granted and assigned to DeuteRx on September, 2013 by the United States Patent and Trademark Office.		‌ DeuteRx	United States Patent and Trademark Office	8524780	September 3, 2013
‌ US Patent 11040925 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same	Patent 11040925 was granted and assigned to DeuteRx on June, 2021 by the United States Patent and Trademark Office.	‌ DeuteRx	‌ DeuteRx	United States Patent and Trademark Office	11040925	June 22, 2021
‌ US Patent 8669268 Deuterium-enriched prasugrel	Patent 8669268 was granted and assigned to DeuteRx on March, 2014 by the United States Patent and Trademark Office.		‌ DeuteRx	United States Patent and Trademark Office	8669268	March 11, 2014
‌ US Patent 9913845 3-(substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same	Patent 9913845 was granted and assigned to DeuteRx on March, 2018 by the United States Patent and Trademark Office.	‌ DeuteRx	‌ DeuteRx	United States Patent and Trademark Office	9913845	March 13, 2018
‌ US Patent 10555946 3-(substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same	Patent 10555946 was granted and assigned to DeuteRx on February, 2020 by the United States Patent and Trademark Office.	‌ DeuteRx	‌ DeuteRx	United States Patent and Trademark Office	10555946	February 11, 2020
‌ US Patent 10202316 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same	Patent 10202316 was granted and assigned to DeuteRx on February, 2019 by the United States Patent and Trademark Office.	‌ DeuteRx	‌ DeuteRx	United States Patent and Trademark Office	10202316	February 12, 2019

22 results

0 selected

22 results

0 selected